Cargando…

A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)

BACKGROUND: The standard 6-month four-drug regimen for the treatment of drug-sensitive tuberculosis has remained unchanged for decades and is inadequate to control the epidemic. Shorter, simpler regimens are urgently needed to defeat what is now the world’s greatest infectious disease killer. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Phillips, Patrick P. J., Dooley, Kelly E., Gillespie, Stephen H., Heinrich, Norbert, Stout, Jason E., Nahid, Payam, Diacon, Andreas H., Aarnoutse, Rob E., Kibiki, Gibson S., Boeree, Martin J., Hoelscher, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804526/ https://www.ncbi.nlm.nih.gov/pubmed/27004726 http://dx.doi.org/10.1186/s12916-016-0597-3

Ejemplares similares

Modifying the multi-arm multi-stage (MAMS) design for use in a phase II tuberculosis trial in sub-Saharan Africa with a time-to-event primary outcome
por: Phillips, Patrick, et al.
Publicado: (2013)

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis
por: Svensson, Elin M, et al.
Publicado: (2018)

Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg(−1) rifampicin
por: te Brake, Lindsey H.M., et al.
Publicado: (2021)

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
por: Boeree, Martin J, et al.
Publicado: (2017)

A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses
por: Svensson, Robin J., et al.
Publicado: (2017)

Tuberculosis Molecular Bacterial Load Assay Reveals Early Delayed Bacterial Killing in Patients With Relapse
por: Ntinginya, Nyanda Elias, et al.
Publicado: (2022)

Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development
por: Ayoun Alsoud, Rami, et al.
Publicado: (2023)

High rifampicin peak plasma concentrations accelerate the slow phase of bacterial decline in tuberculosis patients: Evidence for heteroresistance
por: Martinecz, Antal, et al.
Publicado: (2023)

Transitions between the steps of forward and reverse splicing of group IIC introns
por: Smathers, Claire M., et al.
Publicado: (2020)

Potent Cas9 Inhibition in Bacterial and Human Cells by AcrIIC4 and AcrIIC5 Anti-CRISPR Proteins
por: Lee, Jooyoung, et al.
Publicado: (2018)

Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs
por: Davies, Geraint, et al.
Publicado: (2019)

Pharmacodynamic Biomarkers for Quantifying the Mycobacterial Effect of High Doses of Rifampin in Patients with Rifampin-susceptible Pulmonary Tuberculosis
por: Said, Bibie N, et al.
Publicado: (2021)

Unilateral transnasal endoscopic approach to frontal sinuses: Draf IIc
por: Al Komser, Mohammed K., et al.
Publicado: (2013)

Inhibitory mechanism of CRISPR-Cas9 by AcrIIC4
por: Li, Xuzichao, et al.
Publicado: (2023)

Phenotypic Changes on Mycobacterium Tuberculosis-Specific CD4 T Cells as Surrogate Markers for Tuberculosis Treatment Efficacy
por: Ahmed, Mohamed I. M., et al.
Publicado: (2018)

Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis
por: te Brake, Lindsey H. M., et al.
Publicado: (2019)

Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients
por: Mtabho, Charles M, et al.
Publicado: (2019)

Diversity and strength of internal outward-oriented promoters in group IIC-attC introns
por: Léon, Grégory, et al.
Publicado: (2010)

Protocol for a feasibility randomized controlled trial to evaluate the efficacy, safety and tolerability of N-acetylcysteine in reducing adverse drug reactions among adults treated for multidrug-resistant tuberculosis in Tanzania
por: Mpagama, Stellah G., et al.
Publicado: (2023)

A randomised trial evaluating bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: an update
por: Biswas, S, et al.
Publicado: (2008)

Case Report: Hemophagocytic Lymphocytosis in a Patient With Glutaric Aciduria Type IIC
por: Huang, Lingtong, et al.
Publicado: (2022)

Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis
por: Stemkens, Ralf, et al.
Publicado: (2023)

Rifampicin Can Be Given as Flat-Dosing Instead of Weight-Band Dosing
por: Susanto, Budi O, et al.
Publicado: (2019)

Activation of actin polymerization by phosphatidic acid derived from phosphatidylcholine in IIC9 fibroblasts
Publicado: (1993)

Combination treatment with nivolumab and Rigvir of a progressive stage IIC skin melanoma patient
por: Brokāne, Linda, et al.
Publicado: (2019)

Characterization of the ganglioside recognition profile of Escherichia coli heat-labile enterotoxin LT-IIc
por: Zalem, Dani, et al.
Publicado: (2021)

A redox switch regulates the assembly and anti-CRISPR activity of AcrIIC1
por: Zhao, Yanan, et al.
Publicado: (2022)

Rare portal hypertension caused by Abernethy malformation (Type IIC): A case report
por: Yao, Xin, et al.
Publicado: (2023)

Expression of nonmuscle myosin IIC is regulated by non-canonical binding activity of miRNAs
por: Banerjee, Kumarjeet, et al.
Publicado: (2023)

The MELFO Study: A Multicenter, Prospective, Randomized Clinical Trial on the Effects of a Reduced Stage-Adjusted Follow-Up Schedule on Cutaneous Melanoma IB–IIC Patients—Results After 3 Years
por: Deckers, Eric A., et al.
Publicado: (2019)

Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials
por: Phillips, Patrick P. J., et al.
Publicado: (2016)

Inhibition of CRISPR-Cas9 ribonucleoprotein complex assembly by anti-CRISPR AcrIIC2
por: Thavalingam, Annoj, et al.
Publicado: (2019)

Re-Evaluation of the Survival Paradox Between Stage IIB/IIC and Stage IIIA Colon Cancer
por: Li, Hongbo, et al.
Publicado: (2020)

Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF)
por: Nabisere, Ruth, et al.
Publicado: (2020)

Characterization of the AcrIIC1 anti‒CRISPR protein for Cas9‒based genome engineering in E. coli
por: Trasanidou, Despoina, et al.
Publicado: (2023)

Erratum to: Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials
por: Phillips, Patrick P. J., et al.
Publicado: (2016)

Tuberculosis bacillary load, an early marker of disease severity: the utility of tuberculosis Molecular Bacterial Load Assay
por: Sabiiti, Wilber, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States
por: Zhang, Shujing, et al.
Publicado: (2023)

Influence of M. tuberculosis Lineage Variability within a Clinical Trial for Pulmonary Tuberculosis
por: Nahid, Payam, et al.
Publicado: (2010)

Precision-Enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials
por: Imperial, Marjorie Z., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_im5i5a7pmd281dcabkva6hm2lp